.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA04_Vinorelbine.Vinorelbine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA04_Vinorelbine.Vinorelbine| name: | Vinorelbine |
| ATC code: | L01CA04 | route: | intravenous |
| n-compartments | 3 |
Vinorelbine is a semi-synthetic vinca alkaloid antineoplastic agent that inhibits mitosis by binding to tubulin. It is primarily used in the treatment of non-small cell lung cancer and advanced breast cancer. Vinorelbine is approved and used in clinical oncology practice today.
Pharmacokinetics in adult cancer patients, after intravenous administration, based on population PK modeling.
Pétain, A, et al., & Ferré, P (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. Cancer chemotherapy and pharmacology 84(2) 373–382. DOI:10.1007/s00280-019-03872-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31134323
Nguyen, L, et al., & Variol, P (2002). Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. British journal of clinical pharmacology 53(5) 459–468. DOI:10.1046/j.1365-2125.2002.01581.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11994051
Variol, P, et al., & Puozzo, C (2002). A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. European journal of clinical pharmacology 58(7) 467–476. DOI:10.1007/s00228-002-0506-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12389069